Synopsis Patients who have had acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. The present study aims to determine alirocumab would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high-intensity statin therapy. This week’s “ MED FACT ” discusses a clinical study from The New England Journal of Medicine, “ Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome ”. Nov 2018. Authors : G.G.
Schwartz; P.G. Steg; M. Szarek; et.al. Key Takeaways: The alirocumab lower the risk of recurrent ischemic cardiovascular events in patients who had acute coronary syndrome and who were receiving high-intensity statin therapy. Objective: To determine the efficacy and safety of alirocumab after acute coronary syndrome in patients receiving high-intensity statin therapy Study Type: Multicenter, randomized,…
